Asim Pati, MD
Hematology · Spartanburg, SCNPI 1841294121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.3%.
Across 782 payments — averaging $46.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Sanofi$5K
- Incyte Corporation$4K
- Bristol Myers Squibb$3K
- Beigene USA, Inc.$2K
- Servier Pharmaceuticals LLC$2K
- plus $14K from 54 others
Across 245 payments — averaging $1171.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$162K
- Bristol Myers Squibb$65K
- Pharmacyclics LLC, An Abbvie Company$28K
- Astrazeneca UK Limited$23K
- E.r. Squibb & Sons, L.L.C.$8K
- Janssen Research & Development, LLC$1K
What the payments were for
- Consulting fees$20,15455%
- Travel & lodging$1,3864%
- Food & beverage$14,86741%
- Education$2501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 117 | $1,807,178 |
| CalquenceAcalabrutinib Maleate | 67 | $890,604 |
| SprycelDasatinib | 44 | $706,410 |
| ImbruvicaIbrutinib | 66 | $597,793 |
| PomalystPomalidomide | 22 | $469,451 |
| JakafiRuxolitinib Phosphate | 17 | $286,698 |
| VenclextaVenetoclax | 13 | $166,454 |
| PromactaEltrombopag Olamine | 15 | $146,449 |
| EliquisApixaban | 92 | $77,040 |
| XareltoRivaroxaban | 50 | $37,633 |
| Posaconazole | 11 | $14,845 |
| Hydroxyurea | 123 | $2,246 |
| Allopurinol | 166 | $964 |
| Dexamethasone | 56 | $896 |
| Tamoxifen Citrate | 17 | $891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $3,052 | $1,807,178117 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $863 | $1,175,86166 claims |
| AstraZenecaCalquence | $5,978 | $890,60467 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $251 | $597,79366 claims |
| Incyte CorporationJakafi | $4,282 | $286,69817 claims |
| AbbVieVenclexta | $1,483 | $166,45413 claims |
| NovartisPromacta | $543 | $146,44915 claims |
| PfizerEliquis | $686 | $77,04092 claims |
| Johnson & JohnsonXarelto | $789 | $37,63350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other hematology in Spartanburg
- Hamza HashmiCharleston$244K
- Praneeth BaratamCharleston$157K
- Brian HessCharleston$28K
- Sharif KhanGreenville$7K
- Benjamin DjulbegovicCharleston$4K
- Christopher RangelCharleston$1K
- Jailan OsmanColumbia$440
- Samuel SmithGreenville$15
- Charles GreenbergCharleston$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.